Bayer Logo Bayer Logo Bayer Logo Bayer Logo

PAH FACTS

Adempas is approved for adults with PAH (WHO Group 1) and has been studied predominantly in WHO functional class II-III patients.1

SETTING AND TRACKING YOUR PAH PATIENT GOALS

The 2015 ESC/ERS Guidelines recommend follow-up assessments every 3 to 6 months for stable patients with PAH.2  Since PAH can progress rapidly, it is critical to monitor your patients often.3

ERS=European Respiratory Society; ESC=European Society of Cardiology; PAH=pulmonary arterial hypertension; WHO=World Health Organization

ASSESS AND MONITOR PATIENT RISK STATUS2*
Select a risk level:
Low Risk
Intermediate Risk
High Risk
Low Risk
Low Risk
Intermediate Risk
Intermediate Risk
High Risk
High Risk

The guidelines above can assist with:

  • Creating goals and monitoring progress to help guide the course of treatment
  • Setting goals for your PAH patients that include exercise capacity (6MWD), WHO functional class, and hemodynamics

6MWD=6-minute walk distance;

BNP=brain natriuretic peptide;

CI=cardiac index;

CMR=cardiac magnetic resonance;

NT-proBNP=N-terminal pro-brain natriuretic peptide;

pred.=predicted;

RA=right atrium;

RAP=right atrial pressure;

SvO2=mixed venous oxygen saturation;

VE/VCO2=ventilatory equivalents for carbon dioxide;

VO2=oxygen consumption

Dictionary

CLINICAL DEFINITION

PAH is defined as a mean pulmonary artery pressure (mPAP) >25 mm Hg with a pulmonary capillary wedge pressure (PCWP) ≤15 mm Hg measured by cardiac catheterization.3

Beaker Icon

TREATMENT LANDSCAPE

The REVEAL Registry evaluated 2525 patients, of whom 2438 were on PAH treatment with ERAs, PCAs, or PDE-5 inhibitors. More than 50% of these patients remained in WHO functional class III or IV.4

Evaluation for etiologies other than PAH is appropriate in all instances.
To rule out CTEPH (WHO Group 4), a V/Q scan should be performed.3,5

CTEPH=chronic thromboembolic pulmonary hypertension; ERA=endothelin receptor antagonist; PCA=prostacyclin analog; PDE-5=phosphodiesterase type 5; V/Q=ventilation/perfusion

Alt tag

WHO GROUP CLASSIFICATION1,6

Identify which WHO group your PH patients are in.

I.PAH

II.PH due to left heart disease

III.PH due to lung disease and/or hypoxia

IV.CTEPH

V.PH with unclear multifactorial mechanisms

 

Adempas is approved for adults with PAH (WHO Group 1) and inoperable or persistent/recurrent CTEPH (WHO Group 4) after surgery. Adempas has been studied predominantly in WHO functional class II-III patients.1

PH=pulmonary hypertension

WHO GROUP CLASSIFICATION1,6

Identify which WHO group your PH patients are in.

I.    PAH

II.   PH due to left heart disease

III. PH due to lung disease and/or hypoxia

IV.  CTEPH

V.    PH with unclear multifactorial mechanisms

 

Adempas is approved for adults with PAH (WHO Group 1) and inoperable or persistent/recurrent CTEPH (WHO Group 4) after surgery. Adempas has been studied predominantly in WHO functional class II-III patients.1

PH=pulmonary hypertension

Speed Dial Icon

Learn about efficacy and safety.

Find out how Adempas can help here.

ASSESS AND MONITOR PATIENT RISK STATUS2*
Select a risk level:
Low Risk
Intermediate Risk
High Risk
Low Risk
Low Risk
Intermediate Risk
Intermediate Risk
High Risk
High Risk

The guidelines above can assist with:

  • Creating goals and monitoring progress to help guide the course of treatment
  • Setting goals for your PAH patients that include exercise capacity (6MWD), WHO functional class, and hemodynamics

6MWD=6-minute walk distance;

BNP=brain natriuretic peptide;

CI=cardiac index;

CMR=cardiac magnetic resonance;

NT-proBNP=N-terminal pro-brain natriuretic peptide;

pred.=predicted;

RA=right atrium;

RAP=right atrial pressure;

SvO2=mixed venous oxygen saturation;

VE/VCO2=ventilatory equivalents for carbon dioxide;

VO2=oxygen consumption

Dictionary

CLINICAL DEFINITION

PAH is defined as a mean pulmonary artery pressure (mPAP) >25 mm Hg with a pulmonary capillary wedge pressure (PCWP) ≤15 mm Hg measured by cardiac catheterization.3

Beaker Icon

TREATMENT LANDSCAPE

The REVEAL Registry evaluated 2525 patients, of whom 2438 were on PAH treatment with ERAs, PCAs, or PDE-5 inhibitors. More than 50% of these patients remained in WHO functional class III or IV.4

Evaluation for etiologies other than PAH is appropriate in all instances.
To rule out CTEPH (WHO Group 4), a V/Q scan should be performed.3,5

CTEPH=chronic thromboembolic pulmonary hypertension; ERA=endothelin receptor antagonist; PCA=prostacyclin analog; PDE-5=phosphodiesterase type 5; V/Q=ventilation/perfusion

WHO GROUP CLASSIFICATION1,6

Identify which WHO group your PH patients are in.

I.    PAH

II.   PH due to left heart disease

III. PH due to lung disease and/or hypoxia

IV.  CTEPH

V.    PH with unclear multifactorial mechanisms

 

Adempas is approved for adults with PAH (WHO Group 1) and inoperable or persistent/recurrent CTEPH (WHO Group 4) after surgery. Adempas has been studied predominantly in WHO functional class II-III patients.1

PH=pulmonary hypertension

Speed Dial Icon

Learn about efficacy and safety.

Find out how Adempas can help here.

 
MORE IMPORTANT SAFETY INFORMATION LESS IMPORTANT SAFETY INFORMATION